Free Newsletter
FEATURES >> The most interesting logos in Pharma
Pfizer should partner with Sanofi
It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.
If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.
- read the report from Fortune
Related Articles:
Pfizer-Sanofi match not made in heaven? Report
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Sanofi-Aventis
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
SHARE
WITH: